Gilead Sciences, Inc Insider Trading
Every director, officer and 10% holder of Gilead Sciences, Inc has to report each trade in its stock within two business days of making it. This is those filings.
GILD on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Johanna MercierChief Comm & Corp Aff Officer2026-09-151.6K shat $143.69 | Sale10b5-1 plan | $229.9K |
| Johanna MercierChief Comm & Corp Aff Officer2026-09-15800 shat $144.46 | Sale10b5-1 plan | $115.6K |
| Johanna MercierChief Comm & Corp Aff Officer2026-09-15600 shat $145.29 | Sale10b5-1 plan | $87.2K |
| Andrew D DickinsonChief Financial Officer2026-09-153K shat $145.29 | Sale10b5-1 plan | $435.9K |
| Daniel Patrick O'DayChairman & CEO2026-09-011.6K shat $147.51 | Sale10b5-1 plan | $236K |
| Daniel Patrick O'DayChairman & CEO2026-09-018K shat $148.36 | Sale10b5-1 plan | $1.2M |
| Daniel Patrick O'DayChairman & CEO2026-09-015.4K shat $149.38 | Sale10b5-1 plan | $807.9K |
| Anthony WeltersDirector2026-08-263.1K shat $148.31 | Sale10b5-1 plan | $462.4K |
| Anthony WeltersDirector2026-08-264.6K shat $148.82 | Sale10b5-1 plan | $684.6K |
| Anthony WeltersDirector2026-08-263.4K shat $148.24 | Sale10b5-1 plan | $504.3K |
| Anthony WeltersDirector2026-08-266.9K shat $148.82 | Sale10b5-1 plan | $1M |
| Jeffrey BluestoneDirector2026-08-201.2K shat $143.75 | Sale10b5-1 plan | $167.5K |
| Jeffrey BluestoneDirector2026-08-201.8K shat $144.92 | Sale10b5-1 plan | $263.2K |
| Jeffrey BluestoneDirector2026-08-201.7K shat $145.73 | Sale10b5-1 plan | $241.6K |
| Jeffrey BluestoneDirector2026-08-2026 shat $146.36 | Sale10b5-1 plan | $3.8K |
| Jeffrey BluestoneDirector2026-08-20335 shat $146.26 | Sale10b5-1 plan | $49K |
| Johanna MercierChief Comm & Corp Aff Officer2026-08-1716.5K shat $137.37 | Sale10b5-1 plan | $2.3M |
| Johanna MercierChief Comm & Corp Aff Officer2026-08-1711.5K shat $138.04 | Sale10b5-1 plan | $1.6M |
| Andrew D DickinsonChief Financial Officer2026-08-173K shat $138.36 | Sale10b5-1 plan | $415.1K |
| Daniel Patrick O'DayChairman & CEO2026-08-036.7K shat $129.66 | Sale10b5-1 plan | $868.7K |
| Daniel Patrick O'DayChairman & CEO2026-08-037.7K shat $130.80 | Sale10b5-1 plan | $1M |
| Daniel Patrick O'DayChairman & CEO2026-08-03600 shat $131.34 | Sale10b5-1 plan | $78.8K |
| Johanna MercierChief Comm & Corp Aff Officer2026-07-153K shat $129.92 | Sale10b5-1 plan | $389.8K |
| Andrew D DickinsonChief Financial Officer2026-07-153K shat $129.93 | Sale10b5-1 plan | $389.8K |
| Daniel Patrick O'DayChairman & CEO2026-07-0111.9K shat $126.09 | Sale10b5-1 plan | $1.5M |
| Daniel Patrick O'DayChairman & CEO2026-07-013.1K shat $127.08 | Sale10b5-1 plan | $393.9K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on GILD
Follow Gilead Sciences, Inc (GILD) by email
New trades in Gilead Sciences, Inc (GILD) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.